10815886

pubmed:Citation

5

The aim of this study was to examine the tolerability, antitumor activity, and biological effects of a new schedule of i.v. recombinant human interleukin 12 (rhIL-12). Twenty-eight patients were enrolled in a Phase I trial in which rhIL-12 was administered twice weekly as an i.v. bolus for 6 weeks. Stable or responding patients were eligible to receive additional 6-week cycles until there was no evidence of disease or until tumor progression. Patient cohorts were treated with escalating doses of rhIL-12 (30-700 ng/kg). The maximum tolerated dose (MTD) was 500 ng/kg, with dose-limiting toxicities consisting of elevated hepatic transaminases and cytopenias. At the MTD (n = 14), there was one partial response occurring after 6 cycles of rhIL-12 in a patient with renal cell cancer. Two additional renal cell cancer patients treated at the MTD had prolonged disease stabilization, with one of these exhibiting tumor regression after 8 cycles of rhIL-12. IFN-gamma, IL-15, and IL-18 were induced in patients treated with rhIL-12. Whereas IFN-gamma and IL-15 induction were attenuated midway through the first cycle in patients with disease progression, those patients with tumor regression or prolonged disease stabilization were able to maintain IFN-gamma, IL-15, and IL-18 induction. The down-modulation of IFN-gamma induction during rhIL-12 treatment did not relate to IL-10 production or alterations in rhIL-12 bioavailability but was associated with an acquired defect in lymphocyte IFN-gamma production in response to IL-12, IL-2, or IL-15. This defect could be partially overcome in vitro through combined stimulation with IL-12 plus IL-2. These findings show that the chronic administration of twice-weekly i.v. rhIL-12 is well-tolerated, stimulates the production of IL-12 costimulatory cytokines and IFN-gamma, and can induce delayed tumor regression. Strategies aimed at maintaining IFN-gamma induction, such as the addition of IL-2, may further augment the response rate to this schedule of rhIL-12.

eng

IM

MEDLINE

1078-0432

Print

NLM

1678-92

pubmed-meshheading:10815886-Adult, pubmed-meshheading:10815886-Aged, pubmed-meshheading:10815886-Arthralgia, pubmed-meshheading:10815886-Carcinoma, Renal Cell, pubmed-meshheading:10815886-Dose-Response Relationship, Drug, pubmed-meshheading:10815886-Female, pubmed-meshheading:10815886-Fever, pubmed-meshheading:10815886-Hematologic Diseases, pubmed-meshheading:10815886-Humans, pubmed-meshheading:10815886-Hypotension, pubmed-meshheading:10815886-Injections, Intravenous, pubmed-meshheading:10815886-Interferon-gamma, pubmed-meshheading:10815886-Interleukin-12, pubmed-meshheading:10815886-Interleukin-15, pubmed-meshheading:10815886-Interleukin-18, pubmed-meshheading:10815886-Kidney Neoplasms, pubmed-meshheading:10815886-Male, pubmed-meshheading:10815886-Melanoma, pubmed-meshheading:10815886-Middle Aged, pubmed-meshheading:10815886-Mouth Mucosa, pubmed-meshheading:10815886-Neoplasm Metastasis, pubmed-meshheading:10815886-Recombinant Proteins, pubmed-meshheading:10815886-Skin, pubmed-meshheading:10815886-Stomatitis, pubmed-meshheading:10815886-Time Factors

Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.

Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't, Clinical Trial, Phase I